Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  A, Jiye ^a   Qian, Sixuan ^b   Wang, Guangji ^a   Yan, Bei ^a   Zhang, Sujiang ^b   Huang, Qing ^a   Ni, Lingna ^b   Zha, Weibin ^a   Liu, Linsheng ^a   Cao, Bei ^a   Hong, Ming ^b   Wu, Hanxin ^b   Lu, Hua ^b   Shi, Jian ^a   Li, Mengjie ^a   Li, Jianyong ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AMINO ACID; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYUREA; IMATINIB; LIPID; TRICARBOXYLIC ACID;

ADULT; AGED; AMINO ACID METABOLISM; ARTICLE; BIOMICS; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IN VIVO STUDY; KARYOTYPING; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABONOMICS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UREA CYCLE;

ADULT; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE, NEOPLASM; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MUTATION; PIPERAZINES; PYRIMIDINES;

EID: 78149440003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013186     Document Type: Article

References (44)

1. Fan TW, Higashi RM, Lane AN (2006) Integrating metabolomics and transcriptomics for probing SE anticancer mechanisms. Drug Metab Rev 38: 707-732.
2. Holmes E, Wilson ID, Nicholson JK (2008) Metabolic phenotyping in health and disease. Cell 134: 714-717.
3. Kurzrock R, Gutterman J, Talpaz M (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319: 990-998.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037.
5. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541.
6. Kantarjian H, O'Brien S, Cortes J, Shan J, Giles FJ, et al. (2003) Complete cytogenetic and molecular responses to interferon-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97: 1033-1041.
7. Kantarjian H, Schiffer C, Jones D, Cortes J (2008) Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111: 1774-1780.
8. Oksman-Caldentey KM, Saito K (2005) Integrating genomics and metabolomics for engineering plant metabolic pathways. Curr Opin Biotechnol 16: 174-179.
9. Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, et al. (2003) Imatinib produces significantly superior molecular responses compared to interferon plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17: 2401-2409.
10. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, et al. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108: 28-37.
11. Morvan D, Demidem A (2007) Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res 67: 2150-2159.
12. Ellis DI, Dunn WB, Griffin JL, Allwood JW, Goodacre R (2007) Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 8: 1243-1266.
13. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, et al. (2002) Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med 8: 1439-1444.
14. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, et al. (2005) Metabonomic Identification of Novel Biomarkers of Myocardial Ischemia. Circulation 112: 3868-3875.
15. Xu G, Liebich HM, Lehmann R, Müller-Hagedorn S (2001) Capillary electrophoresis of urinary normal and modified nucleosides of cancer patients. Methods Mol Biol 162: 459-474.
16. Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, et al. (2008) Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer 7: 72.
17. Li M, Wang B, Zhang M, Rantalainen M, Wang S, et al. (2008) Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 105: 2117-2122.
18. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, et al. (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073-1077.
19. Nicholson JK, Lindon JC (2008) Systems biology: metabonomics. Nature 455: 1054-1056.
20. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, et al. (2009) Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines. Public Library of Sciences (PLoS) 4(1): e4251.
21. Jonsson P, Johansson AI, Gullberg J, Trygg J, A J, et al. (2005) High-throughput data analysis for detecting and identifying differences between samples in GC/ MS-based metabolomic analyses. Anal Chem 77: 5635-5642.
22. A J, Trygg J, Gullberg J, Johansson AI, Jonsson P, et al. (2005) Extraction and GC/MS Analysis of the human blood plasma metabolome. Anal Chem 77: 8086-8094.
23. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S (2001) Multi- and megavariate data analysis principles and applications. Umetrics AB, Sweden.
24. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, et al. (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354: 2006-2013.
25. Gottardi M, Manzato E, Gherlinzoni F (2005) Imatinib and hyperlipidemia. N Engl J Med 353: 2722-2723.
26. Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gambacorti- Passerini C (2008) Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica 93: 317-318.
27. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ (2004) Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCRABL- positive cells. Clin Cancer Res 10: 6661-6668.
28. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-46.
29. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233.
30. Chen Z, Lu W, Garcia-Prieto C, Huang P (2007) The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39: 267-274.
31. Keurentjes JJ, Fu J, de Vos C, Lommen A, Hall RD, et al. (2006) The genetics of plant metabolism. Nat Genet 38: 842-849.
32. Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107: 76-94.
33. Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, et al. (2010) SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 115: 1049-1053.
34. Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1018-1029.
35. Zheng C, Li L, Haak M, Brors B, Frank O, et al. (2006) Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20: 1028-1034.
36. Yong AS, Szydlo RM, Goldman JM, Apperley JF, Melo JV (2006) Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107: 205-212.
37. McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, et al. (2010) A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 115: 315-325.
38. Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, et al. (2009) Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res 15: 3442-3450.
39. Sviridov D, Nestel P (2002) Dynamics of reverse cholesterol transport: Protection against atherosclerosis. Atherosclerosis 161: 245-254.
40. Batetta B, Sanna F (2006) Cholesterol metabolism during cell growth: Which role for the plasma membrane? Eur. J. Lipid Sci. Technol 108: 687-699.
41. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nat Rev Cancer 5: 173-183.
42. Rowley JD, Blumenthal T (2008) Medicine. The cart before the horse. Science 321: 1302-1304.
43. Mitelman F (1995) ISCN an international system for human cytogenetic nomenclature. Basel: S. Karger.
44. Trygg J, Holmes E, Lundstedt T (2007) Chemometrics in metabonomics J Proteome Res 6: 469-479.